Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.

A number of other analysts have also recently commented on the company. EF Hutton Acquisition Co. I upgraded Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th. HC Wainwright reiterated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Wednesday, August 14th.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $1.12 on Thursday. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $2.15. The firm has a market capitalization of $60.82 million, a price-to-earnings ratio of -1.90 and a beta of 0.51. The company has a current ratio of 2.12, a quick ratio of 1.71 and a debt-to-equity ratio of 0.82. The firm has a 50 day moving average of $1.14 and a 200 day moving average of $1.00.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $9.89 million for the quarter, compared to analysts’ expectations of $9.73 million. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. During the same quarter last year, the company posted ($0.14) EPS. On average, research analysts anticipate that Cytosorbents will post -0.32 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CTSO. Key Client Fiduciary Advisors LLC increased its stake in Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares in the last quarter. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the third quarter worth about $51,000. CM Management LLC boosted its stake in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares during the period. Sargent Investment Group LLC grew its position in shares of Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares in the last quarter. Finally, Avenir Corp raised its stake in Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after purchasing an additional 121,294 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.